Coronavirus Drug Discovery
Volume 2: Antiviral Agents from Natural Products and Nanotechnological Applications
- 1st Edition - July 7, 2022
- Imprint: Elsevier
- Editor: Chukwuebuka Egbuna
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 5 5 7 4 - 4
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 5 5 7 5 - 1
Coronavirus Drug Discovery, Volume Two: Antiviral Agents from Natural Products and Nanotechnological Applications presents detailed information on drug discovery against COVID-19.… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteCoronavirus Drug Discovery, Volume Two: Antiviral Agents from Natural Products and Nanotechnological Applications presents detailed information on drug discovery against COVID-19. Sections in this volume present chapters that focus on the various antiviral agents from natural products that have the propensity to be used as chemical scaffolds for the development of drugs against COVID-19. Also captured are the dietary sources of antioxidant bioactives that may help boost the immune system for the management of COVID-19. Other chapters describe the application of nanotechnology for efficient and effective delivery of drugs against COVID-19.
Written by global team of experts, this book is an excellent resource for drug developers, medicinal chemists, pharmaceutical companies in R&D and research institutes in both academia and industry.
- Presents the various antiviral bioactive compounds from natural products
- Discusses the roles of antioxidant in the prevention and management of COVID-19
- Details the application of nanotechnology for efficient and effective drug delivery
Researchers in organic and medicinal chemistry including drug developers and medicinal chemists, virologists, toxicologists, analytical chemists.Researchers in pharmaceutical and biotech industries
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- Part I. Antiviral agents from natural products
- Chapter 1. COVID-19 management and phytomedicine interventions: potentials and safety considerations
- 1.1. Introduction
- 1.2. Modes of transmission
- 1.3. Understanding the pathophysiology of the COVID-19 infection
- 1.4. Priming the immune system: effect of immune boosters on susceptibility to COVID-19 infection
- 1.5. Reduction of the viral load: potential utilization of medicinal plants
- 1.6. Safety issues in the consideration of phytomedicine interventions in the management of COVID-19
- 1.7. Future projections
- 1.8. Conclusion
- Chapter 2. Antiviral effects of medicinal plants and their active phytochemical constituents against respiratory diseases and associated biological functions
- 2.1. Introduction
- 2.2. Respiratory viral infections
- 2.3. Viral respiratory diseases and their pathogens
- 2.4. Plant species used in treatment of viral respiratory infections
- 2.5. Conclusions and future perspectives
- Chapter 3. Herbs and drugs in clinical trials for coronavirus treatments
- 3.1. Introduction
- 3.2. Coronavirus
- 3.3. Symptoms and management of coronavirus disease
- 3.4. Clinical trials for coronavirus treatments
- 3.5. Future projections
- 3.6. Conclusion
- Chapter 4. Bioactive compounds and herbal preparations implicated in the treatment of SARS-CoV-2
- 4.1. Introduction
- 4.2. Treatment protocols
- 4.3. Herbal therapies
- 4.4. Limitations of the use of herbal medicine
- 4.5. Future perspectives
- 4.6. Conclusion
- Chapter 5. Roles of antioxidants in the prevention and management of coronavirus disease 2019
- 5.1. Introduction
- 5.2. Oxidative stress and viral infections
- 5.3. Immune systems and viral infections
- 5.4. Antioxidants supporting optimal immune function
- 5.5. Antioxidants against viral diseases
- 5.6. Phytochemicals for boosting immunity against coronaviruses
- 5.7. Peptide-derived antioxidant components
- 5.8. Micronutrients against viral diseases
- 5.9. Future projections
- 5.10. Conclusion
- Chapter 6. Food sources of natural antioxidants for body defense against SARS-CoV-2
- 6.1. Introduction
- 6.2. The role of nutrition in the strengthening of the immune system against SARS-CoV-2
- 6.3. Antioxidants, nutrition micro-ingredients necessary to fight infection
- 6.4. Plants with medical properties
- 6.5. Use of plants as a source of natural antioxidants
- 6.5. African origin of sources of vitamins against SARS-CoV-2
- 6.6. Future perspectives
- 6.7. Conclusion
- Chapter 7. Nutritional management against severe acute respiratory syndrome coronavirus-2 infection
- 7.1. Introduction
- 7.2. Nutritional requirements
- 7.3. Basic macronutrient need
- 7.4. Micronutrients
- 7.5. Nutritional supplements
- 7.6. Future perspectives
- 7.7. Conclusion
- Chapter 8. Plants sources of vitamins against SARS-CoV-2
- 8.1. Introduction
- 8.2. Plants as a valuable source of vitamins and other bioactives
- 8.3. Future perspectives
- 8.4. Conclusion
- Chapter 9. Microorganisms as potential source of drug for SARS-CoV-2 (COVID-19): antimicrobial drugs-ivermectin, azithromycin
- 9.1. Introduction
- 9.2. Prevention and control
- 9.3. Vaccines against COVID-19
- 9.4. Suggestive approaches against SARS-CoV-2
- 9.5. The antimicrobials: ivermectin and azithromycin
- 9.6. Future prospects
- 9.7. Conclusion
- Chapter 10. Drug discovery opportunities from traditional practices against SARS-CoV-2: Madagascar COVID organics and the use of mugwort plant
- 10.1. Introduction
- 10.2. Treatment options using conventional medicine
- 10.3. Management of COVID-19 from traditional practices
- 10.4. Antiviral compounds from medicinal plants
- 10.5. Madagascar COVID organics and the use of mugwort plant against SARS-CoV-2
- 10.6. Future perspectives
- 10.7. Conclusion
- Chapter 11. Marine organisms as a potential source of antiviral drugs for the treatment of coronavirus infections and other viral diseases
- 11.1. Introduction
- 11.2. Compounds from marine organisms with antiviral activity and their sources
- 11.3. Marine organisms as potential sources of antiviral agents against coronavirus
- 11.4. Marine organisms as potential sources of antiviral agents against COVID-19
- 11.5. Future perspectives
- 11.6. Conclusion
- Chapter 12. Antiviral potentials of marine algal bioactive compounds for coronavirus drug discovery
- 12.1. Introduction
- 12.2. Bioactive compounds from algae
- 12.3. Future projections
- 12.4. Conclusion
- Part II. Application of nanotechnology in coronavirus drug discovery
- Chapter 13. Application of nanotechnology in drug development and delivery for SARS-CoV-2 treatment
- 13.1. Introduction
- 13.2. Nanosized drug carriers
- 13.3. Nano-based drug delivery systems
- 13.4. Drug targeting
- 13.5. Mechanism of action of COVID-19
- 13.6. Current treatment methods for COVID-19
- 13.7. Intranasal drug delivery using nanocarriers
- 13.8. Nanoparticles-based treatment modalities
- 13.9. Future projections
- 13.10. Conclusion
- Chapter 14. Nanocarriers as potential and effective delivery tool for COVID-19 drugs
- 14.1. Introduction
- 14.2. Nanotechnology approach
- 14.3. Nanocarriers as an effective delivery tool
- 14.4. Theranostic nanocarriers
- 14.5. Virus-like NPs
- 14.6. Self-assembling protein NPs (SAPNPs)
- 14.7. Nano biosensors
- 14.8. Conclusion
- Chapter 15. Nanomaterials for the rapid diagnosis of SARS-CoV-2 and other viral infections
- 15.1. Introduction
- 15.2. Nanomaterials in the diagnosis of microbial infections
- 15.3. Nanomaterials for the diagnosis of viral infections
- 15.4. Nanomaterials for the diagnosis of pandemic viral infections
- 15.5. The necessity to develop rapid diagnostic methods
- 15.6. Nanomaterials for COVID-19 diagnosis
- 15.7. Mechanism of COVID-19 diagnosis using nanomaterials
- 15.8. Conclusion
- Chapter 16. Nanocarriers as delivery tool for COVID-19 drugs
- 16.1. Introduction
- 16.2. Repurposing of drugs and their nanopotentiation
- 16.3. Nanopotentiation of potential drugs against COVID-19
- 16.4. Regulatory aspects of nanopotentiated products for COVID-19
- 16.5. Future perspective
- 16.6. Conclusion
- Chapter 17. Plant-based nanoformulations for human viral diseases: an emphasis on COVID-19
- 17.1. Introduction
- 17.2. Nanoparticles and their mode of viral inhibition
- 17.3. Plant-based nanoformulations
- 17.4. Possible mode of action of nanoparticles against SARS-CoV-2
- 17.5. Recent developments in nanoformulations for tackling 2019-nCoV
- 17.6. Future projections
- 17.7. Conclusion
- Index
- Edition: 1
- Published: July 7, 2022
- No. of pages (Paperback): 382
- No. of pages (eBook): 382
- Imprint: Elsevier
- Language: English
- Paperback ISBN: 9780323955744
- eBook ISBN: 9780323955751
CE
Chukwuebuka Egbuna
Chukwuebuka Egbuna (PhD) is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Dr. Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs, and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited more than 25 books with Elsevier, Springer, Wiley, and Taylor & Francis. His most recent book is the three volume Coronavirus Drug Discovery, published by Elsevier. Dr. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services.
Affiliations and expertise
Africa Centre of Excellence in Public Health and Toxicological Research, University of Port Harcourt, NigeriaRead Coronavirus Drug Discovery on ScienceDirect